Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series

被引：0

作者：

Teoli, M. ^{[1
]}

Mandel, V. D. ^{[1
]}

Franceschini, C. ^{[1
]}

Saraceni, P. L. ^{[2
]}

Cicini, M. P. ^{[3
]}

Ardigo, M. ^{[1
]}

机构：

[1] San Gallicano Dermatol Inst IRCCS, Porphyria & Rare Dis Unit, Rome, Italy

[2] San Gallicano Dermatol Inst IRCCS, Clin Dermatol Dept, Rome, Italy

[3] Natl Canc Inst Regina Elena IRCCS, Cardiol Dept, Rome, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2022年 / 26卷 / 21期

关键词：

Cutaneous T-cell lymphoma; Mogamulizumab; Bexarotene; CCR4; Sezary syndrome; Mycosis fungoides; Systemic; therapy; Chemotherapy; PHASE-II; GEMCITABINE TREATMENT; BRENTUXIMAB VEDOTIN; PHYSICIANS CHOICE; MYCOSIS-FUNGOIDES; TRIAL; MULTICENTER; VORINOSTAT; ROMIDEPSIN; PERSISTENT;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BACKGROUND: Treatment choices for patients with advanced-stage mycosis fungoides (MF) or Sezary syndrome (SS) who have failed first-line systemic therapies can be challenging, as several options are available. However, most evidence is based on observational and early phase studies due to the rarity of the disease. Mogamulizumab has recently been approved for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy; it has a good tolerability profile prompting its use in combination with other agents. This article aims at describing the role of the concomitant use of bexarotene with mogamulizumab in this setting. CASES PRESENTATION: To add information in the field, we describe our experience with four patients with MF/SS who failed first- and second-line treatments and started the combination mogamulizumab in addition to bexarotene. The combination of bexarotene with mogamulizumab in patients with advanced MF/SS after the failure of bexarotene alone obtained a response in all the four patients observed. The response was maintained longer than expected.

引用

页码：8118 / 8128

页数：11

共 37 条

[21] Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma [J].

Kim, Ellen J. ;

Kim, Youn H. ;

Rook, Alain H. ;

Lerner, Adam ;

Duvic, Madeleine ;

Reddy, Sunil ;

Robak, Tadeusz ;

Becker, Juergen C. ;

Samtsov, Alexey ;

McCulloch, William ;

Waksman, Joel ;

Whittaker, Sean .

LEUKEMIA & LYMPHOMA, 2015, 56 (10) :2847-2854

[22] What factors guide treatment selection in myco sis fungoides and Sezary syn drome ? [J].

Kim, Youn H. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) :303-312

[23] Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [J].

Kim, Youn H. ;

Bagot, Martine ;

Pinter-Brown, Lauren ;

Rook, Alain H. ;

Porcu, Pierluigi ;

Horwitz, Steven M. ;

Whittaker, Sean ;

Tokura, Yoshiki ;

Vermeer, Maarten ;

Zinzani, Pier Luigi ;

Sokol, Lubomir ;

Morris, Stephen ;

Kim, Ellen J. ;

Ortiz-Romero, Pablo L. ;

Eradat, Herbert ;

Scarisbrick, Julia ;

Tsianakas, Athanasios ;

Elmets, Craig ;

Dalle, Stephane ;

Fisher, David C. ;

Halwani, Ahmad ;

Poligone, Brian ;

Greer, John ;

Fierro, Maria Teresa ;

Khot, Amit ;

Moskowitz, Alison J. ;

Musiek, Amy ;

Shustov, Andrei ;

Pro, Barbara ;

Geskin, Larisa J. ;

Dwyer, Karen ;

Moriya, Junji ;

Leoni, Mollie ;

Humphrey, Jeffrey S. ;

Hudgens, Stacie ;

Grebennik, Dmitri O. ;

Tobinai, Kensei ;

Duvic, Madeleine .

LANCET ONCOLOGY, 2018, 19 (09) :1192-1204

[24] Adverse cardiovascular events in patients treated with mogamulizumab [J].

Kwan, Jennifer M. ;

Henry, Mariana L. ;

Cook, Kirstin ;

Higgins, Angela ;

Cuomo, Jason ;

Foss, Francine ;

Baldassarre, Lauren A. .

AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2021, 9

[25] Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines [J].

Mehta-Shah, Neha ;

Horwitz, Steven M. ;

Ansell, Stephen ;

Ai, Weiyun Z. ;

Barnes, Jeffrey ;

Berta, Stefan K. ;

Clemens, Mark W. ;

Dogan, Ahmet ;

Fisher, Kristopher ;

Goodman, Aaron M. ;

Goyal, Gaurav ;

Guitart, Joan ;

Halwani, Ahmad ;

Haverkos, Bradley M. ;

Hoppe, Richard T. ;

Jacobsen, Eric ;

Jagadeesh, Deepa ;

Lunning, Matthew A. ;

Mehta, Amitkumar ;

Olsen, Elise A. ;

Pro, Barbara ;

Rajguru, Saurabh A. ;

Shanbhag, Satish ;

Shaver, Aaron ;

Shustov, Andrei ;

Sokol, Lubomir ;

Torka, Pallawi ;

Torres-Cabala, Carlos ;

Wilcox, Ryan ;

William, Basem M. ;

Zain, Jasmine ;

Dwyer, Mary A. ;

Sundar, Hema ;

Kim, Youn H. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (05) :523-536

[26] Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma [J].

Olsen, Elise A. ;

Kim, Youn H. ;

Kuzel, Timothy M. ;

Pacheco, Theresa R. ;

Foss, Francine M. ;

Parker, Sareeta ;

Frankel, Stanley R. ;

Chen, Cong ;

Ricker, Justin L. ;

Arduino, Jean Marie ;

Duvic, Madeleine .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) :3109-3115

[27]

Olsen Elise A, 2003, Dermatol Ther, V16, P311, DOI 10.1111/j.1396-0296.2003.01643.x

[28] Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sezary Syndrome [J].

Photiou, Louise ;

van der Weyden, Carrie ;

McCormack, Christopher ;

Prince, H. Miles .

CURRENT ONCOLOGY REPORTS, 2018, 20 (04)

[29] Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma [J].

Piekarz, Richard L. ;

Frye, Robin ;

Turner, Maria ;

Wright, John J. ;

Allen, Steven L. ;

Kirschbaum, Mark H. ;

Zain, Jasmine ;

Prince, H. Miles ;

Leonard, John P. ;

Geskin, Larisa J. ;

Reeder, Craig ;

Joske, David ;

Figg, William D. ;

Gardner, Erin R. ;

Steinberg, Seth M. ;

Jaffe, Elaine S. ;

Stetler-Stevenson, Maryalice ;

Lade, Stephen ;

Fojo, A. Tito ;

Bates, Susan E. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) :5410-5417

[30] Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [J].

Prince, H. Miles ;

Kim, Youn H. ;

Horwitz, Steven M. ;

Dummer, Reinhard ;

Scarisbrick, Julia ;

Quaglino, Pietro ;

Zinzani, Pier Luigi ;

Wolter, Pascal ;

Sanches, Jose A. ;

Ortiz-Romero, Pablo L. ;

Akilov, Oleg E. ;

Geskin, Larisa ;

Trotman, Judith ;

Taylor, Kerry ;

Dalle, Stephane ;

Weichenthal, Michael ;

Walewski, Jan ;

Fisher, David ;

Dreno, Brigitte ;

Stadler, Rudolf ;

Feldman, Tatyana ;

Kuzel, Timothy M. ;

Wang, Yinghui ;

Palanca-Wessels, Maria Corinna ;

Zagadailov, Erin ;

Trepicchio, William L. ;

Zhang, Wenwen ;

Lin, Hui-Min ;

Liu, Yi ;

Huebner, Dirk ;

Little, Meredith ;

Whittaker, Sean ;

Duvic, Madeleine .

LANCET, 2017, 390 (10094) :555-566

← 1 2 3 4 →